You are here

Israeli biotech firm surges on mystery firm's nameless analyst note

Tel Aviv

WHEN Pluristem Therapeutics Inc, an Israeli developer of experimental stem-cell treatments, rose 39 per cent in Nasdaq trading last week, traders attributed it to a bullish report on a website linked to a California biotech pundit.

The two-page report from Acceleron Equity...

Market voices on: